1. Scrip
  2. >>Business

Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane

Outlines Impact Of China Zero-COVID Policy

 
• By Anju Ghangurde

Generic Revlimid, lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.

New Revenue Base For Cipla's US business • Source: Shutterstock

Cipla Limited signaled a new revenue base for its US business in the fiscal second quarter, buoyed by the ongoing market share expansion of its partnered peptide asset lanreotide and the launch of generic Revlimid (lenalidomide).

Cipla’s 505(b)(2) hybrid lanreotide injection product has seen market share move up to 9.6% in the second quarter, from 4

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.